Panasonic Receives Highest Award of Brand Design at the Automotive Brand Contest 2020
30.6.2020 04:12:00 EEST | Business Wire | Press release
On June 30, 2020, Panasonic Corporation announced that it has received the highest accolade as Best of Best in the Brand Design category at the Automotive Brand Contest 2020, which is organized by German Design Council (Rat für Formgebung). The award was given in recognition of the concept and design of the Panasonic Automotive business brand. The official award ceremony is planned to take place in autumn 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005891/en/
Panasonic Automotive's brand design that received the highest award of brand design at the Automotive Brand Contest 2020 (Graphic: Business Wire)
The Automotive Brand Contest is the only international design competition for automotive brands. The German Design Council, founded in 1953, also runs internationally renowned design awards, such as the German Design Award and the ICONIC Awards.
The Automotive Brand Contest covers all creative aspects in the automotive industry across the world – from vehicle design to corporate publishing. This year's winners also include global brands, such as Audi, BMW, Buick, Byton, Continental, Mercedes-Benz, Porsche and Volkswagen. Panasonic is the first Japanese automotive supplier to be awarded Best of Best in the contest’s history which started in 2011.
In praise of Panasonic Automotive’s brand design, the contest jury said, “The consistent appearance in light blue and green unobtrusively underscores the clear positioning of the Panasonic Automotive brand, where it transitions from a vision into reality, from innovation to automotive solutions, thus becoming convincingly tangible.”
The development of the brand’s concept and design was initiated in Europe from the spring of 2017. The process adopted a collaborative approach with clients. Brand concept and design was developed through basing on clients’ image and expectation on Panasonic. Additionally, several options were reviewed by clients as well as automotive media persons before making the final decision.
Panasonic Automotive’s brand concept and design is adopted not only in Europe but also globally, including China and Japan. It was first presented at its booth at the Shanghai Motor Show in April 2019.
Panasonic continues to strive to enhance the recognition and understandings of its automotive business through the Panasonic Automotive brand and increase the brand value of the company.
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global.
Source: https://news.panasonic.com/global/topics/2020/79235.html
Related Links
Automotive Company, Panasonic Corporation
https://www.panasonic.com/global/corporate/am.html
Panasonic Business Brands
https://www.panasonic.com/global/corporate/brand/our-brand/business_brand.html
Automotive Brand Contest 2020
https://www.automotive-brand-contest.de/en.html
[Press Release] Toyota and Panasonic Decide to Establish Joint Venture Specializing in Automotive Prismatic Batteries (Feb 3, 2020)
https://news.panasonic.com/global/press/data/2020/02/en200203-4/en200203-4.html
[Press Release] Panasonic Develops a Driverless Automated Valet Parking System and a Large Screen AR-HUD (Oct 11, 2019)
https://news.panasonic.com/global/press/data/2019/10/en191011-2/en191011-2.html
[Press Release] Panasonic to Showcase Booth at 26th ITS World Congress Singapore 2019 (Oct 10, 2019)
https://news.panasonic.com/global/press/data/2019/10/en191010-3/en191010-3.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005891/en/
Contact information
Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom